Selpercatinib
- Generic Name
- Selpercatinib
- Brand Names
- Retevmo, Retsevmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O3
- CAS Number
- 2152628-33-4
- Unique Ingredient Identifier
- CEGM9YBNGD
- Background
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-dri...
- Indication
Selpercatinib is approved to treat:
Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.
- Associated Conditions
- Locally Advanced Solid Neoplasm, Metastatic Solid Neoplasm, Advanced RET-fusion thyroid cancer, Advanced RET-mutant medullary thyroid cancer, Metastatic RET-fusion Non Small Cell Lung Cancer, Metastatic RET-fusion thyroid cancer, Metastatic RET-mutant medullary thyroid cancer
- Associated Therapies
- -
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 80
- Registration Number
- NCT06532149
- Locations
- ๐ฎ๐น
Fondazione Policlinico Gemelli IRCCS, Rome, Italy
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05906836
- Locations
- ๐บ๐ธ
Labcorp Clinical Research LP, Dallas, Texas, United States
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05668962
- Locations
- ๐บ๐ธ
University of Michigan, Ann Arbor, Michigan, United States
๐บ๐ธMedStar Washington Hospital Center, Washington, D.C., District of Columbia, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05630274
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT05630287
- Locations
- ๐บ๐ธ
LabCorp CRU, Inc., Madison, Wisconsin, United States
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT05469113
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT05468164
- Locations
- ๐บ๐ธ
Celerion, Tempe, Arizona, United States
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT05469100
- Locations
- ๐บ๐ธ
Orange County Research Center, Tustin, California, United States
๐บ๐ธStanford Health Care, Valley Care Program, Pleasanton, California, United States
๐บ๐ธAnaheim Regional Center, Anaheim, California, United States
A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT05436912
- Locations
- ๐บ๐ธ
Orange County Research Center, Tustin, California, United States
๐บ๐ธOrange County Research Institute, Anaheim, California, United States
๐บ๐ธRiverside Clinical Research, Edgewater, Florida, United States
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT05364645
- Locations
- ๐บ๐ธ
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
๐บ๐ธUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธSutter Auburn Faith Hospital, Auburn, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.